Ultra Nasdaq Biotechnology

ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the NASDAQ Biotechnology Index®.

View Prospectus (PDF) | Download Fact Sheet (PDF)

Get News Updates

View News Center

Index/Benchmark Summary

The NASDAQ Biotechnology Index is a modified capitalization weighted index that includes securities of The NASDAQ Stock Market listed companies that are classified as either biotechnology or pharmaceutical. The securities also meet other eligibility criteria determined by The NASDAQ OMX Group, Inc., including minimum market capitalization and liquidity requirements.

Fundamentals as of 3/31/14

Total Number of Companies 121
Price/Earnings Ratio 34.85
Price/Book Ratio 7.97
Dividend Yield *(%) 0.20
Average Index Market Capitalization $5.56 billion

* Derivative contracts are priced to reflect the underlying index yield and will not generate dividend income. Because ProShares invest in derivatives, they will not have dividend distributions that reflect those of their applicable indexes.

Index Holdings Information as of 3/31/14

Top 10 Index Companies Weight
Amgen Inc. 8.92%
Biogen Idec Inc. 8.05%
Celgene Corp. 7.79%
Gilead Sciences Inc. 7.68%
Alexion Pharmaceuticals Inc. 6.79%
Regeneron Pharmaceuticals Inc. 4.05%
Vertex Pharmaceuticals Inc. 3.92%
Illumina Inc. 3.89%
BioMarin Pharmaceutical Inc. 2.37%
Incyte Corp. 2.14%

ProShares may invest in financial instruments (including derivatives) that, in combination, should have similar daily price return characteristics to the fund's benchmark.

Index Sector Weightings § Weight
Biotechnology 74.47%
Pharmaceuticals 22.61%
Health Care Products 2.54%
Diversified 0.24%
Commercial Services 0.14%

§ Sum of weightings may not equal 100% due to rounding.